TEL AVIV, Israel, Aug. 8, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2017.
Highlights and achievements during the second quarter 2017 and to date:
Continued execution on multiple clinical development programs for the Company’s lead project, BL-8040:
